DrugCite
Search

ETOPOSIDE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Etoposide Adverse Events Reported to the FDA Over Time

How are Etoposide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Etoposide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Etoposide is flagged as the suspect drug causing the adverse event.

Most Common Etoposide Adverse Events Reported to the FDA

What are the most common Etoposide adverse events reported to the FDA?

Febrile Neutropenia
1104 (2.52%)
Neutropenia
873 (1.99%)
Pyrexia
702 (1.6%)
Sepsis
640 (1.46%)
Thrombocytopenia
564 (1.29%)
Vomiting
516 (1.18%)
Pneumonia
515 (1.18%)
Nausea
452 (1.03%)
Diarrhoea
442 (1.01%)
Pancytopenia
434 (.99%)
Mucosal Inflammation
430 (.98%)
Show More Show More
Hypotension
408 (.93%)
Renal Failure Acute
373 (.85%)
Anaemia
368 (.84%)
Dyspnoea
340 (.78%)
White Blood Cell Count Decreased
334 (.76%)
Respiratory Failure
324 (.74%)
Acute Myeloid Leukaemia
284 (.65%)
Platelet Count Decreased
284 (.65%)
Haemoglobin Decreased
281 (.64%)
Infection
281 (.64%)
Septic Shock
272 (.62%)
Leukopenia
268 (.61%)
Dehydration
257 (.59%)
Renal Failure
257 (.59%)
Fatigue
251 (.57%)
Bone Marrow Failure
245 (.56%)
Death
244 (.56%)
Asthenia
243 (.56%)
Pleural Effusion
236 (.54%)
Multi-organ Failure
206 (.47%)
Disease Progression
193 (.44%)
Headache
193 (.44%)
Myelodysplastic Syndrome
192 (.44%)
Confusional State
182 (.42%)
Stem Cell Transplant
179 (.41%)
Hypokalaemia
178 (.41%)
Hypoxia
177 (.4%)
Malignant Neoplasm Progression
176 (.4%)
Drug Toxicity
172 (.39%)
Neutropenic Sepsis
170 (.39%)
Abdominal Pain
169 (.39%)
Hypertension
164 (.37%)
Pneumocystis Jiroveci Pneumonia
164 (.37%)
Convulsion
163 (.37%)
Neutrophil Count Decreased
161 (.37%)
Acute Respiratory Distress Syndrome
157 (.36%)
Tachycardia
148 (.34%)
Pulmonary Oedema
145 (.33%)
Stomatitis
145 (.33%)
Blood Creatinine Increased
138 (.32%)
Pulmonary Embolism
138 (.32%)
Respiratory Distress
138 (.32%)
Alanine Aminotransferase Increased
134 (.31%)
Oesophagitis
134 (.31%)
Off Label Use
134 (.31%)
Colitis
133 (.3%)
Cardiac Arrest
131 (.3%)
Staphylococcal Infection
131 (.3%)
Chills
130 (.3%)
Deep Vein Thrombosis
127 (.29%)
Drug Ineffective
126 (.29%)
Tumour Lysis Syndrome
126 (.29%)
Encephalopathy
125 (.29%)
General Physical Health Deteriorati...
122 (.28%)
Dysphagia
120 (.27%)
Blood Culture Positive
118 (.27%)
Lung Infiltration
115 (.26%)
Renal Impairment
115 (.26%)
Ascites
114 (.26%)
Cough
112 (.26%)
Hyponatraemia
109 (.25%)
Aspartate Aminotransferase Increase...
108 (.25%)
Fall
107 (.24%)
Pain
106 (.24%)
Pneumonitis
106 (.24%)
Blood Bilirubin Increased
105 (.24%)
Venoocclusive Liver Disease
104 (.24%)
Fungal Infection
103 (.24%)
Interstitial Lung Disease
103 (.24%)
Atrial Fibrillation
102 (.23%)
Gastrointestinal Haemorrhage
100 (.23%)
Caecitis
98 (.22%)
Cerebral Haemorrhage
98 (.22%)
Disseminated Intravascular Coagulat...
97 (.22%)
Myocardial Infarction
96 (.22%)
Chest Pain
94 (.21%)
Dizziness
93 (.21%)
Cardiac Failure
92 (.21%)
Mental Status Changes
91 (.21%)
Back Pain
89 (.2%)
Lung Infection
89 (.2%)
Haematocrit Decreased
88 (.2%)
Pulmonary Haemorrhage
88 (.2%)
Metastasis
87 (.2%)
Respiratory Disorder
87 (.2%)
Drug Interaction
86 (.2%)
Osteonecrosis
86 (.2%)
Neoplasm Malignant
85 (.19%)
Arthralgia
84 (.19%)
Cardio-respiratory Arrest
84 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Etoposide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Etoposide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Etoposide

What are the most common Etoposide adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Etoposide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Etoposide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Etoposide According to Those Reporting Adverse Events

Why are people taking Etoposide, according to those reporting adverse events to the FDA?

Acute Myeloid Leukaemia
839
Multiple Myeloma
590
Acute Lymphocytic Leukaemia
525
Non-hodgkins Lymphoma
518
Small Cell Lung Cancer Stage Unspec...
513
Hodgkins Disease
478
Show More Show More
Diffuse Large B-cell Lymphoma
375
Testis Cancer
248
Lymphoma
236
Chemotherapy
226
Germ Cell Cancer
219
Non-small Cell Lung Cancer
199
Burkitts Lymphoma
172
Product Used For Unknown Indication
145
B-cell Lymphoma
144
Medulloblastoma
142
Drug Use For Unknown Indication
141
Ewings Sarcoma
120
Neuroblastoma
108
Stem Cell Transplant
105
Bone Sarcoma
100
Rhabdomyosarcoma
100
Mantle Cell Lymphoma
100
Small Cell Lung Cancer Extensive St...
98
Bone Marrow Conditioning Regimen
93
Non-small Cell Lung Cancer Stage Ii...
90
Lung Neoplasm Malignant
88
Testicular Germ Cell Cancer
80
Prostate Cancer
70
Histiocytosis Haematophagic
58
Neoplasm Malignant
58
Ovarian Cancer
56
Adult T-cell Lymphoma/leukaemia
56
Gestational Trophoblastic Tumour
54
Choriocarcinoma
51
Retinoblastoma
47
Acute Promyelocytic Leukaemia
44
Bone Marrow Transplant
43
Myelodysplastic Syndrome
43
Acute Lymphocytic Leukaemia Recurre...
42
Seminoma
41
T-cell Lymphoma Stage Iv
39
Chronic Lymphocytic Leukaemia
35
Nephroblastoma
33
Lymphohistiocytosis
33
T-cell Lymphoma
31
B Precursor Type Acute Leukaemia
30
Primitive Neuroectodermal Tumour
28
Sarcoma
27
Leukaemia
25
Central Nervous System Lymphoma
25

Drug Labels

LabelLabelerEffective
EtoposideMylan Pharmaceuticals Inc.11-SEP-06
EtoposideBedford Laboratories18-MAY-10
EtoposideBedford Laboratories18-MAY-10
EtoposideAccord Healthcare Inc.02-FEB-11
EtopophosE.R. Squibb & Sons, L.L.C.17-MAR-11
ToposarTeva Parenteral Medicines, Inc14-AUG-12
EtoposideAPP Pharmaceuticals, LLC30-AUG-12

Etoposide Case Reports

What Etoposide safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Etoposide. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Etoposide.